GlaxoSmithKline’s consumer healthcare venture with Pfizer will be named Haleon, as the British drugmaker confirmed the business will be spun off in mid-2022 as planned after having rejected overtures from Unilever.
Engitix Therapeutics raised $54 million in Series A financing. Engitix plans to use the money to boost the company’s drug discovery pipeline in fibrosis and cancer and expand its team, facilities and operations.
Sanofi raised the company’s 2021 profit forecast on July 29 after its vaccines and star eczema treatment Dupixent helped the French drugmaker beat second-quarter results expectations.
FDA delays decision on Bristol Myers cancer therapy due to Covid-19 travel curbsAcquisitions, Biologics License Application (BLA), Blood Cancers, Bristol Myers Squibb, Business, Coronavirus Restrictions, Facilities/Sites/Manufacturing, FDA, Investors, R&D, Relapsed Or Refractory (R/R) Large B-Cell Lymphoma (LBCL), Texas
Bristol Myers Squibb said the U.S. health regulator deferred a decision on an experimental blood cancer therapy that the company acquired in the $74 billion buyout of Celgene due to coronavirus-related travel restrictions.
San Diego-based Engrail Therapeutics launched with $32 million in a Series A financing round that was solely funded by Nan Fung Life Sciences (NFLS).
Menlo Park, California-based Orca Bio closed on a Series D financing worth $192 million, bringing the total raised since 2016 to $300 million.
Intra-Cellular Therapies Inc.’s lead drug to treat schizophrenia in adults received approval from the U.S. Food and Drug Administration, sending the company’s shares soaring 85 percent.
Sage Therapeutics Inc.’s experimental fast-acting drug aimed at treating severe depression failed a closely-watched study, sending shares down 60 percent and erasing about $4.6 billion of the drugmaker’s market value.
U.S. drugmaker Bristol-Myers Squibb Co. reported higher-than-expected third-quarter 2019 profit, helped by strong sales of the blood thinner Eliquis, even as growth of the company’s blockbuster cancer treatment Opdivo slowed.
AstraZeneca reported positive results from clinical trial programs for Brilinta and Farxiga, causing stock to jump 3.4 percent.